Natera, Inc. (NTRA)
After hours:
| Previous Close | 93.72 |
| Open | 95.88 |
| Bid | 96.86 x 100 |
| Ask | 97.00 x 100 |
| Day's Range | 95.00 - 97.44 |
| 52 Week Range | 36.90 - 98.82 |
| Volume | |
| Avg. Volume | 1,370,848 |
| Market Cap | 11.855B |
| Beta (5Y Monthly) | 1.39 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera™ in Breast Cancer
AUSTIN, Texas, May 03, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced a new publication in JCO Precision Oncology reporting on the ability of its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, to detect recurrence early in patients with early-stage breast cancer. The full study can be found here.
- Business Wire
Natera to Report its First Quarter 2024 Results on May 9
AUSTIN, Texas, May 01, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its first quarter ended March 31, 2024, after the market close on May 9, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET).
- Business Wire
Natera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage
AUSTIN, Texas, May 01, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of a new cfDNA-based fetal RhD test. This comes at a critical time for the healthcare industry, helping physicians navigate patient care given nationwide shortages of Rho(D) immune globulin therapy (RhIg).
